# Fibrosis or steatosis: which is the best screening target? Comment on the Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity

**Authors:** Mateus Dornelles Severo

PMC · DOI: 10.20945/2359-4292-2024-0014 · 2024-06-03

## Full-text entities

- **Diseases:** MASLD (MESH:D008107), metabolic dysfunction-associated (MESH:D008659), Fibrosis (MESH:D005355), obesity (MESH:D009765), steatosis (MESH:D005234), overweight (MESH:D050177)

---
Source: https://tomesphere.com/paper/PMC11192477